Baseline characteristics and CVR factors
| Whole cohort . | CVR comparison according to CACS in 308-patient subset without prior CAD or HF . | ||||
|---|---|---|---|---|---|
| Characteristics . | n (%) . | CACS = 0 (N = 202) . | CACS 1-400 (N = 73) . | CACS >400 (N = 33) . | P value . |
| Total | 308 (100) | 202 | 73 | 33 | NA |
| Male sex | 199 (56) | 97 (48%) | 48 (66%) | 22 (67%) | .011 |
| Median age, y (range) | 66 (19-93) | 55 (19-93) | 69 (44-93) | 72 (46-89) | <.001 |
| No. of chemotherapy cycles, median (range) | 6 (1-6) | 6 (1-6) | 6 (1-6) | 6 (1-6) | .646 |
| Mediastinal radiotherapy exposure | 9 (3) | 8 (4%) | 1 (1%) | 0 (0%) | .301 |
| Modifiable CVR factors | |||||
| BMI ≥25 | 212 (59) | 102 (51%) | 54 (74%) | 19 (57.6%) | .002 |
| eGFR <45 | 33 (9) | 14 (7%) | 5 (7%) | 4 (12.1%) | .56 |
| Hypercholesterolaemia | 100 (28) | 28 (14%) | 26 (36%) | 16 (48.5%) | <.001 |
| Hypertension | 138 (39) | 48 (24%) | 33 (45%) | 20 (60.6%) | <0.001 |
| Diabetes | 64 (18) | 16 (8%) | 21 (42.9%) | 12 (36.4%) | <.001 |
| Smoking history | 130 (36) | 63 (31%) | 25 (23.6%) | 19 (57.6%) | .049 |
| Any cardiac risk factor | 239 (67) | 110 (55%) | 54 (28.1%) | 29 (90%) | <.001 |
| ≥2 cardiac risk factors | 135 (38) | 42 (21%) | 31 (32.3%) | 23 (70%) | <.001 |
| Median number cardiac RFs (range) | 1 (0-4) | 1 (0-4) | 1 (0-4) | 2 (0-4) | <.001 |
| Cardiac events on treatment | |||||
| New arrhythmia | 20 (6) | 7 (3.5%) | 3 (4%) | 6 (18%) | .002 |
| New heart failure | 26 (7) | 6 (3%) | 9 (12%) | 6 (18%) | <.001 |
| New CAD | 11 (3) | 1 (0.5%) | 2 (3%) | 1 (3%) | .222 |
| Any cardiac event | 44 (12) | 11 (5.4%) | 13 (18%) | 8 (24.2%) | <.001 |
| Months to first cardiac event, median (range) | 14.5 (1-104) | 72 (6-104) | 14 (6-84) | 5 (1-54) | .002 |
| Diagnosis | |||||
| DLBCL | 275 (77) | ||||
| Other high-grade DLBCL | 24 (7) | ||||
| PTCL | 2 (1) | ||||
| HL | 55 (15) | ||||
| Indolent lymphoma | 2 (1) | ||||
| Whole cohort . | CVR comparison according to CACS in 308-patient subset without prior CAD or HF . | ||||
|---|---|---|---|---|---|
| Characteristics . | n (%) . | CACS = 0 (N = 202) . | CACS 1-400 (N = 73) . | CACS >400 (N = 33) . | P value . |
| Total | 308 (100) | 202 | 73 | 33 | NA |
| Male sex | 199 (56) | 97 (48%) | 48 (66%) | 22 (67%) | .011 |
| Median age, y (range) | 66 (19-93) | 55 (19-93) | 69 (44-93) | 72 (46-89) | <.001 |
| No. of chemotherapy cycles, median (range) | 6 (1-6) | 6 (1-6) | 6 (1-6) | 6 (1-6) | .646 |
| Mediastinal radiotherapy exposure | 9 (3) | 8 (4%) | 1 (1%) | 0 (0%) | .301 |
| Modifiable CVR factors | |||||
| BMI ≥25 | 212 (59) | 102 (51%) | 54 (74%) | 19 (57.6%) | .002 |
| eGFR <45 | 33 (9) | 14 (7%) | 5 (7%) | 4 (12.1%) | .56 |
| Hypercholesterolaemia | 100 (28) | 28 (14%) | 26 (36%) | 16 (48.5%) | <.001 |
| Hypertension | 138 (39) | 48 (24%) | 33 (45%) | 20 (60.6%) | <0.001 |
| Diabetes | 64 (18) | 16 (8%) | 21 (42.9%) | 12 (36.4%) | <.001 |
| Smoking history | 130 (36) | 63 (31%) | 25 (23.6%) | 19 (57.6%) | .049 |
| Any cardiac risk factor | 239 (67) | 110 (55%) | 54 (28.1%) | 29 (90%) | <.001 |
| ≥2 cardiac risk factors | 135 (38) | 42 (21%) | 31 (32.3%) | 23 (70%) | <.001 |
| Median number cardiac RFs (range) | 1 (0-4) | 1 (0-4) | 1 (0-4) | 2 (0-4) | <.001 |
| Cardiac events on treatment | |||||
| New arrhythmia | 20 (6) | 7 (3.5%) | 3 (4%) | 6 (18%) | .002 |
| New heart failure | 26 (7) | 6 (3%) | 9 (12%) | 6 (18%) | <.001 |
| New CAD | 11 (3) | 1 (0.5%) | 2 (3%) | 1 (3%) | .222 |
| Any cardiac event | 44 (12) | 11 (5.4%) | 13 (18%) | 8 (24.2%) | <.001 |
| Months to first cardiac event, median (range) | 14.5 (1-104) | 72 (6-104) | 14 (6-84) | 5 (1-54) | .002 |
| Diagnosis | |||||
| DLBCL | 275 (77) | ||||
| Other high-grade DLBCL | 24 (7) | ||||
| PTCL | 2 (1) | ||||
| HL | 55 (15) | ||||
| Indolent lymphoma | 2 (1) | ||||
BMI, body mass index; DLBCL, diffuse large B-cell lymphoma; eGFR, estimated glomerular filtration rate; HL, Hodgkin lymphoma; PTCL, peripheral T-cell lymphoma; RFs, risk factors.
Values in bold indicate statistically significant P values <0.05.